Previous Close | 0.0900 |
Open | 0.0900 |
Bid | 0.0900 x 0 |
Ask | 0.0950 x 0 |
Day's Range | 0.0900 - 0.0900 |
52 Week Range | 0.0800 - 0.1900 |
Volume | |
Avg. Volume | 63,261 |
Market Cap | 11.235M |
Beta (5Y Monthly) | 0.33 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0420 |
Earnings Date | May 26, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, June 30, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announces that, following the approval of the shareholders of the Company (the “Shareholders”) at the annual general and special meeting of Shareholders held on May 26, 2022, the Company adopted the second amended and restated stock option plan of the Company and the amended and restated perform
WINNIPEG, Manitoba, June 15, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has further amended its credit agreement with Pivot Financial Inc. (“Pivot”) maturing August 31, 2022 (the “Amended Credit Facility”). The amendment dated June 13, 2022 extends the maturity to January 31, 2023 and increases the credit facility to $4 million with approximately $1.8 million of new capital having been provided. The increased cr
WINNIPEG, Manitoba, May 26, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced its first quarter 2022 financial results. First Quarter Financial Highlights: Total revenue in the three months ended March 31, 2022, was $565,433, an increase of 50% compared to $376,039 in the t